Health & Fitness
Tue, March 17, 2009Mon, March 16, 2009Sun, March 15, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009Thu, February 19, 2009Wed, February 18, 2009Tue, February 17, 2009Mon, February 16, 2009Fri, February 13, 2009Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call
Published in Health and Fitness on Tuesday, February 24th 2009 at 14:08 GMT, Last Modified on 2009-02-24 14:09:29 by Market Wire
LYON, France--([ BUSINESS WIRE ])--Flamel Technologies (Nasdaq:FLML) expects to release its financial results for the fourth quarter and the fiscal year 2008 on Wednesday, March 4th, after the market close. A conference call to discuss the results has been scheduled for Thursday, March 5th, at 8:30 AM (Eastern). A question and answer period is expected to follow the discussion of results.
To participate in the conference call, investors in the US and Canada are invited to dial 1-800-374-1498. International callers are invited to call 1-706-634-7261. The Conference ID number is: 87424852.The conference call webcast may be accessed at [ www.flamel.com ].
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled-release and taste-masking technology for the oral administration of small molecule drugs; it is the intellectual platform licensed by GlaxoSmithKline for the development of Coreg CR™. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides.
This document contains a number of matters, particularly as related to financial projections and the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances.
These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2007.
